The global PD-L1 Biomarker Testing Market is witnessing robust expansion as precision oncology, immunotherapy adoption, and ...

When your care team starts discussing treatment for head and neck cancer, you may hear the term PD-L1, which stands for programmed death-ligand 1. Testing for PD-L1 helps your oncologist determine ...

Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...

GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...

This retrospective observational study reviewed electronic medical records for all patients with lung cancer diagnosed at King Hussein Cancer Center from January 1, 2017, to April 1, 2024. Included ...

Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework Observational studies or ...

US FDA approves expanded use of Agilent’s PD-L1 IHC 22C3 pharmDx on Dako Omnis in ESCC, TNBC, and gastric or gastroesophageal junction adenocarcinoma: Santa Clara, California Fr ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...

Patients with previously untreated advanced squamous non-small-cell lung cancer lived significantly longer without their ...

The global PD-L1 Biomarker Testing Market is witnessing robust expansion as precision oncology, immunotherapy adoption, and biomarker-driven treatment ...